| (1) |
| The “Amount Registered” represents 5,000,000 Class A Ordinary Shares, $0.0001 par value per share (“Ordinary Shares”), of MoonLake Immunotherapeutics issuable under the Plan. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 also includes additional Ordinary Shares in respect of the securities identified in the above table that may become issuable through the Plan as a result of any scrip dividend, sub-division of shares, recapitalization or other similar transactions. The “Proposed Maximum Offering Price Per Share” and the “Maximum Aggregate Offering Price” are estimated solely for calculating the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act, on the basis of the average of the high and low sale prices of the Ordinary Shares on The Nasdaq Stock Market LLC on August 4, 2026, within five business days prior to filing. |